Myristoyl/Palmitoy| Oxostearamide/ Arachamide MEA, Vs Hydroxypropyl Bispalmitamide MEA,, Hydroxypropyl Bislauramide MEA
Searching the Web
Myristoyl Palmitoyl Oxostearamide Arachamide MEA ceramide skincare function
Searching the Web
Hydroxypropyl Bispalmitamide MEA Hydroxypropyl Bislauramide MEA ceramide comparison skincare
Reading Web Page
https://www.lesliebaumannmd.com/why-myristoyl-palmitoyl-oxos…
Here is a thorough side-by-side breakdown:
Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA vs. Hydroxypropyl Bispalmitamide MEA / Hydroxypropyl Bislauramide MEA
Both are pseudo-ceramides (synthetic mimics of natural ceramides) used in skincare to support the stratum corneum barrier. They differ meaningfully in structure, mechanism, and formulation behavior.
1. Chemical Identity
| Property | Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA | Hydroxypropyl Bispalmitamide MEA | Hydroxypropyl Bislauramide MEA |
|---|---|---|---|
| Also known as | MLE technology / "Atopalm" ceramide | Ceramide PC-104 | Ceramide PC-102 (shorter chain variant) |
| Backbone | Fatty acid amide chains (myristoyl/palmitoyl) attached to an ethanolamine (MEA) with oxostearamide/arachamide head | Hydroxypropyl backbone with two palmitoyl (C16) chains + MEA groups | Same hydroxypropyl backbone with two lauryl (C12) chains + MEA groups |
| Sphingosine moiety? | Yes - structurally closer to true ceramides | No - lacks the sphingosine base | No - lacks the sphingosine base |
| True ceramide? | Closer to ceramide NP/AP types | No - confirmed pseudo-ceramide by spectroscopy (Chong & Khoo, 2022, IOP Conf. Ser.) | No - pseudo-ceramide |
The key structural difference: natural ceramides and Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA contain a sphingoid base, which is what defines a true ceramide. The Hydroxypropyl Bis- ingredients replace that base with a simpler hydroxypropyl diamine scaffold bearing two fatty acid chains.
2. Mechanism of Action
Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA (MLE Technology)
- Specifically designed to self-assemble into multi-lamellar emulsion (MLE) structures - alternating lipid bilayers that precisely replicate the lamellar bodies naturally found between corneocytes in the stratum corneum.
- The lamellar organization is what makes this ingredient particularly effective: it doesn't just deposit lipids, it inserts them into the correct ordered crystalline-like arrangement.
- Shown to restore barrier function in atopic dermatitis by rebalancing both the lipid ratios AND the lamellar pattern.
- Developed by MiMedx/Atopalm; key ingredient in Atopalm products.
Hydroxypropyl Bispalmitamide MEA (C16 chains)
- Mimics ceramide 3 (Ceramide NP) in function - fills in gaps in the stratum corneum lipid matrix.
- The C16 palmitoyl chains match the dominant fatty acid length in natural ceramides, giving good lamellar packing compatibility.
- Lower melting point than natural ceramides, making it easier to incorporate into emulsions at lower temperatures.
- Claimed equivalent moisturizing and barrier-restoring efficacy to Ceramide 3, though the structural difference (no sphingosine) means the interaction with the SC lipid matrix is chemically distinct.
Hydroxypropyl Bislauramide MEA (C12 chains)
- Shorter lauryl (C12) chains vs. palmitoyl (C16) - lighter feel, less occlusive.
- Often used alongside Bispalmitamide MEA (as in the Aestura AtoBarrier 365 formula) to broaden the range of lipid chain lengths, better mimicking the natural diversity of ceramide species.
- The shorter chains may contribute more to surface-feel and spreading than deep barrier repair.
3. Performance Comparison
| Attribute | Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA | Hydroxypropyl Bispalmitamide MEA | Hydroxypropyl Bislauramide MEA |
|---|---|---|---|
| Barrier repair depth | Strong - lamellar re-organization | Moderate-strong - lipid gap filling | Moderate - surface-level occlusion |
| Clinical evidence | Atopic dermatitis, TEWL reduction | Mild-moderate AD (Draelos, 2018; Koh, 2017) | Limited solo data; used in combination |
| Structural fidelity to native ceramide | Higher | Lower (no sphingosine) | Lower (no sphingosine, shorter chains) |
| Formulation ease | Requires MLE emulsification technology | Easier - lower melting point | Easiest - shortest chains, most fluid |
| Cost | Higher | Mid-range | Mid-range |
| Skin feel | Richer, slightly heavier | Smooth, emollient | Lighter, silkier |
| Typical use case | Eczema/AD repair creams, compromised barrier products | General moisturizers, barrier creams | Combination with Bispalmitamide for texture |
4. Where You'll Find Them
- Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA: Atopalm MLE Cream, EpiCeram, some prescription barrier emollients.
- Hydroxypropyl Bispalmitamide MEA + Bislauramide MEA together: Aestura AtoBarrier 365 Cream (a well-regarded Korean skincare product for atopic/sensitive skin), as well as several Mamonde and COSRX ceramide products.
5. Bottom Line
- If you want the most structurally faithful ceramide mimic with proven lamellar organization and the strongest barrier repair profile - especially for eczema/atopic dermatitis - Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA (MLE tech) is the more sophisticated option.
- Hydroxypropyl Bispalmitamide MEA is a cost-effective, easily formulated pseudo-ceramide that delivers solid moisturization and barrier support, well-suited for mass-market products.
- Hydroxypropyl Bislauramide MEA is rarely used alone - it pairs with Bispalmitamide MEA to diversify chain-length coverage and improve texture/spreadability.
- Neither Hydroxypropyl Bis- ingredient contains a sphingosine moiety, so they are not technically ceramides by spectroscopic analysis - though they still function as effective barrier-supporting lipids.
Stronger at barrier repair?
Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA is stronger at barrier repair. Here's why, briefly:
The core reason: It uses MLE (multi-lamellar emulsion) technology, meaning it doesn't just deposit lipids into the skin - it self-assembles into the same ordered lamellar bilayer stacks that native stratum corneum lipids form. The organization of lipids matters as much as their presence. A disordered lipid layer leaks.
The Hydroxypropyl Bis- ingredients fill gaps in the SC lipid matrix, but they lack the sphingosine moiety and don't self-organize into the same crystalline lamellar pattern. They work more like a patch than a rebuild.
Analogy: MLE tech is like re-laying bricks in the correct mortared pattern. Bispalmitamide/Bislauramide MEA is like pouring filler into the cracks - useful, but not the same structural result.
Clinically: MLE-based formulas have shown TEWL (trans-epidermal water loss) reduction and improvement in atopic dermatitis severity scores. The Hydroxypropyl Bis- ingredients have supporting evidence too (Draelos 2018 on mild-moderate AD), but the structural argument and the clinical depth of MLE data favor the Myristoyl/Palmitoyl Oxostearamide/Arachamide MEA side.
Caveat: Formulation context matters a lot. A product with Hydroxypropyl Bispalmitamide MEA that also includes cholesterol, free fatty acids, and phytosphingosine in the right ratios can perform comparably - because you're reconstructing the full barrier lipid system, not relying on a single ingredient. The Aestura AtoBarrier 365 formula does exactly this, which is why it performs well despite using pseudo-ceramides rather than MLE tech.
So in isolation: MLE tech wins. In a well-designed full-system formula: the gap narrows considerably.
This is a shared conversation. Sign in to Orris to start your own chat.